Innovent Biologics (HK:1801) has released an update.
Innovent Biologics has announced that China’s National Medical Products Administration (NMPA) accepted the New Drug Application for picankibart, a treatment for moderate to severe plaque psoriasis. The drug, an IL-23p19 antibody, demonstrated high efficacy and safety in Phase 3 trials, with promising results such as over 80% of subjects achieving significant skin lesion clearance. Picankibart is poised to improve treatment convenience and quality of life for patients, backed by Innovent’s commitment to meet regulatory standards for a better treatment option in China.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
